EUCTR2004-000530-37-LT进行中（未招募）不适用
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects with moderate to severe plaque psoriasis. - N/A
Serono International S.A.0 个研究点目标入组 460 人开始时间: 2004年10月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent, given before any study-related procedure not part of the subject’s normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his or her future medical care.
- •2. At least 18 years of age.
- •3. Female subjects must be neither pregnant nor breast-feeding, and must lack childbearing potential, as defined by either:·
- •Being post-menopausal (i.e. at least 12 months past last menses) or surgically sterile, or
- •Using an effective form of contraception (i.e. condoms, oral contraceptives or IUD).
- •Confirmation that the subject is not pregnant must be established by a negative urinary hCG test within 7 days before Study Day 1 (SD1). A pregnancy test is not required if the subject is post-menopausal or surgically sterile.
- •4. Outpatient status at the time of enrolment.
- •5. Plaque psoriasis for at least 12 months.
- •6. Plaque psoriasis covering at least 10% of total body surface area and a PASI score of 12.0 or more.
- •7. Candidacy for phototherapy or systemic therapy.
- •8. Static PGA of 3 or more.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Use of more than one NSAID to treat psoriatic arthritis or having a change in chronic NSAID regimen during the 28 days before SD1. Note for guidance: subjects with psoriatic arthritis who are not expected to be controlled by one stable NSAID regimen throughout the entire duration of the study should not be included.
- •Clarification: see amendment 2
- •2. Previous systemic treatment with biologics, including interferon and other cytokines/anti?cytokines (e.g. anti-TNF-alpha, anti-CD4, IL-10, IL-1ra, anti-CD11a) within 3 months before SD1
- •3. Participation in any other investigational study or experimental therapeutic procedure that is considered to interfere with the study within 3 months before SD1.
- •Clarification: see amendment 2
- •4. Treated with any systemic corticosteroids or intra-articular corticosteroid injection during the 28 days prior to SD1
- •5. Experimental or off-label treatments for psoriasis and/or psoriatic arthritis, such as azathioprine, hydroxyurea/hydroxycarbamide, mycophenolate, chlorambucil, leflunomide or cyclophosphamide, within 1 year prior to SD1
- •6. Treatment with cyclosporin, methotrexate, oral retinoids retinoids (i.e acetretin), or fumaric acid esters within 28 days (3 months for acetretin) before SD1
- •7. Treatment with any topical therapies, such as vitamin D derivatives, corticosteroids, tars and tar oils, dithranol for chronic or short contact therapy, salicylic acid and topical retinoids, within 14 days before SD1
- •8. Phototherapy within 28 days prior to SD1
- •9. Use of tanning booths within 14 days before SD1
- •10. Abnormal liver function, defined by a total bilirubin = 1.2 times the upper limit of normal values (except in case of Gilbert’s syndrome), or aspartate aminotransferase, alanine aminotransferase or total alkaline phosphatase levels = 2.5 times the upper limit of normal values
- •11. Inadequate bone marrow reserve, defined by Leucocytes =3.5 x 109/L, thrombocytes =100 x 109/L, or Haemoglobin =5.5 mmol/L (8.9 g/dL)
- •12. Abnormal renal function, defined by serum creatinine >150 micromol/L
- •13. Seropositivity for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- •Clarification: see amendment 2
- •14. Planned major surgery within the treatment period of the study
- •15. History of cancer in the preceding 5 years (except adequately treated basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin). Any history of hematopoietic cancer
- •16. History of active tuberculosis, current active tuberculosis or candidacy for prophylactic therapy for tuberculosis (see Appendix I for guidance on PPD testing, chest X-ray screening and evaluation of patients at high risk for tuberculosis)
- •17. Active severe infection (or non-severe infection at the discretion of the Investigator)
- •18. History of any opportunistic infection (e.g., viral, fungal, protozoal, or bacterial) in the 6 months preceding SD1 related to any clinical condition of immunodeficiency
- •19. Clinically significant and serious abnormalities on electrocardiography or chest X-ray (at the investigator’s discretion)
- •20. Other serious concomitant disorders incompatible with the study. In particular, subjects with congestive heart failure, prior or current history of blood dyscrasia or central nervous system demyelinating disorders should not be included in the study
- •21. History of drug (including narcotics) abuse, or current active problems with alcohol abuse
- •22. Requirement for immunisation
研究者
相似试验
进行中（未招募）
不适用
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects with moderate to severe plaque psoriasis. - N/AEUCTR2004-000530-37-LVSerono International S.A.460
进行中（未招募）
不适用
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects with moderate to severe plaque psoriasis. - N/APsoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickened erythematous patches typically covered with a silver scale.MedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-000530-37-EESerono International S.A.460
已完成
2 期
A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy - the RESMAIN Studycutaneous lymphomaMycosis fungoides / Sézary Syndrome10025321NL-OMON557444SC AG3
进行中（未招募）
1 期
The purpose of this research study is to determine if the new drug resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have achieved disease control with previous systemic therapy, recentlyAdvanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapyMedDRA version: 20.0Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864EUCTR2016-000807-99-GB4SC AG150
进行中（未招募）
1 期
The purpose of this research study is to determine if the new drug resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have achieved disease control with previous systemic therapy, recentlyAdvanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapyMedDRA version: 19.0Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864EUCTR2016-000807-99-ES4SC AG150